Taste Change Data May Inform Radiotherapy Strategy in Head and Neck Cancer

Commentary
Video

Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.

In a conversation with CancerNetwork® during the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, Noah S. Kalman, MD, MBA, discussed the potential clinical applicability of findings from a prospective study highlighting substantial taste changes among patients who undergo radiotherapy for head and neck cancer.

Kalman, a radiation oncologist specializing in the treatment of gynecologic, head and neck, thoracic and pediatric cancers, melanoma and non-melanoma skin cancers, and sarcoma at Miami Cancer Institute of Baptist Health Medical Group, explained that findings presented at ASTRO affirm the importance of avoiding radiotherapy dosing to the oral cavity whenever possible for this population.

Additionally, data on how dosing to the oral cavity may cause taste changes in patients can help providers consider the potential trade-offs of dosing to different structures. According to Kalman, these findings may also inform treatment decision-making regarding the selection of radiotherapy modalities such as proton therapy, photon therapy, or intensity-modulated radiotherapy (IMRT).

Transcript:

In terms of the clinical applicability of these findings, it adds to the importance of avoiding dosing to the oral cavity when possible for these patients. When we’re developing treatment plans for our [patients with] head and neck cancer, the radiation plans already are working to decrease the dose as much as possible to the oral cavity to reduce the risk of mucositis and other effects. Knowing or having further evidence that the dose of the oral cavity affects the taste changes will perhaps add to the conversation of the trade-offs between doses to different structures and may add consideration if patients or providers are considering different modalities of treatment such as proton therapy vs photon therapy or IMRT. If there’s the ability to drive down the dose to the oral cavity significantly, that can have a benefit for patients in their degree of taste change during treatment.

Reference

Yarlagadda S, Alzmanzar A, Rubens M, Kalman N. Taste changes in patients receiving head and neck radiation – initial analysis from a prospective study. Presented at: 2024 American Society for Radiation Oncology Annual Meeting; September 29-October 2, 2024; Washington, DC. Abstract 3762.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content